News and Media

Eradivir in the News

Featured

Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a study of influenza therapeutic
Purdue University News
Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.
Read More
September 23, 2024
Biotech company Eradivir is developing lead drug EV25 to treat influenza
Purdue University News
Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low’s lab at Purdue University to focus on a platform of immunotherapies for viral infections like influenza and other diseases.
Read More
July 9, 2024

Academia

Featured academic papers.